Ongoing studies include the Columbus-AD study (NCT05270044) evaluating the efficacy and safety of 12 months of BRAF (encorafenib) and MEK (binimetinib) inhibitors versus placebo in resected stage IIA/B/C melanoma patients. This evidence concerns the gene BRAF and melanoma.